altropane
Small moleculeexperimental
Altropane is a phenyltropane derivative which acts as a potent dopamine reuptake inhibitor and long-acting stimulant drug. It has mainly been used as the 125I radiolabelled form for mapping the distribution of dopamine transporters in the brain, and consequently this has led to its development as a potential diagnostic tool for early detection of Parkinson's disease. It is also being investigated for potential use in the diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00397228)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I- Mol. weight
- 429.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAltropane ↗
- ChEMBLCHEMBL4301492 ↗
Also known as
- 2-carbomethoxy-3-(4-fluorophenyl)-n-(1-iodoprop-1-en-3-yl)nortropane
- altropane
- altropane
- altropane
- altropane
- altropane
- altropane
- iacft
- n-iodoallyl-2-carbomethoxy-3-(4-fluorophenyl)tropane
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00397228 | Phase 2 | Nov 1, 2006 | Institute for Neurodegenerative Disorders, Molecular NeuroImaging |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institute for Neurodegenerative Disorders | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Molecular NeuroImaging | For profit | 1 | 1 | 1 | 2006 |
2 organizations
Page 1 / 1